PF-03814735 is a small molecule inhibitor of the checkpoint kinase 1 (CHK1) enzyme, which is involved in the regulation of the cell cycle and DNA damage response. It was first discovered in 2007 and has since been studied for its potential as a treatment for various types of cancer.
Chemical name:
The chemical name for PF-03814735 is N-(2-aminoethyl)-5-chloro-6-[(2-methylphenyl)sulfonyl]-4-[(3-pyridinyl)methyl]indoline-1-carboxamide.
Molecular formula:
The molecular formula of PF-03814735 is C27H26ClN5O3S.
Formula weight:
The formula weight of PF-03814735 is 534.05 g/mol.
CAS No:
The CAS number of PF-03814735 is 942487-16-3.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
PF-03814735 has been primarily developed for the treatment of cancer. As an inhibitor of CHK1, it is thought to sensitize cancer cells to DNA-damaging agents, leading to apoptosis (programmed cell death) and inhibition of tumor growth.
Potential effects:
Some potential effects of PF-03814735 include:
Product mechanism:
PF-03814735 works by inhibiting CHK1, which is a key regulator of the cell cycle and DNA damage response. By inhibiting CHK1, PF-03814735 can sensitize cancer cells to DNA-damaging agents, leading to apoptosis (programmed cell death) and inhibition of tumor growth.
Safety:
PF-03814735 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with PF-03814735.
Side effects:
PF-03814735 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of PF-03814735 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 5 to 30 mg/kg. In clinical trials, doses ranged from 25 to 300 mg once daily. The drug is typically administered orally.
Conclusion:
PF-03814735 is a small molecule inhibitor of CHK1 that has shown potential as a treatment for various types of cancer. By inhibiting CHK1, PF-03814735 may sensitize cancer cells to DNA-damaging agents, leading to apoptosis (programmed cell death) and inhibition of tumor growth. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of PF-03814735 in treating various types of cancer.
